ZUPLENZ (ondansetron) by Novartis is serotonin 3 receptor antagonists [moa]. First approved in 2010.
Drug data last refreshed 3h ago · AI intelligence enriched 6h ago
ZUPLENZ is an oral film formulation of ondansetron, a serotonin 3 receptor antagonist used to prevent nausea and vomiting in patients undergoing chemotherapy or post-operative recovery. The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and GI tract. It represents a convenient alternative to traditional tablet or IV administration.
Product is in peak-to-decline transition with high competitive pressure (8/10), signaling potential contraction of brand team and shift toward defensive positioning.
Serotonin 3 Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study
Ondansetron for the Management of Atrial Fibrillation
Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy
Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron
Worked on ZUPLENZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on ZUPLENZ offers limited career growth potential given the product's peak-to-decline trajectory and high competitive saturation. Positions on this brand are ideal for early-career professionals seeking stability in a mature portfolio product or for those seeking experience in generic/commodity market dynamics before transitioning to growth-stage products.